← All stocks

Prelude Therapeutics Inc

PRLD Net buying
CIK 0001678660 #3089 in the set updated 17 Sep 2026
Bought (12 mo)
$25.00M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$25.00M
+$25.00M against sales at will

By person

7 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Bonita David P
Director
$12.50M (2)
+$12.50M
1,126,126
1.41%
$5.00M
ORBIMED ADVISORS LLC entity
Director
$12.50M (2)
+$12.50M
1,126,126
1.41%
$5.00M
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
6,475,882
8.11%
$28.75M
−17.8%
Vaddi Krishna
CEO
2,141,849
2.68%
$9.51M
+80.3%
Combs Andrew
Chief Chemistry Officer
480,123
0.6016%
$2.13M
+51.4%
Huang Jane
President, CMO
86,917
0.1089%
$385.91K
+51.6%
Lim Bryant David
CLO, CFO, Corp Sec.
27,400
0.0343%
$121.66K
+1,042%
Insider
Date
Role
Action
Shares
Price
Amount
ORBIMED ADVISORS LLC
21 Apr 2026
Director
Buy indirect
1,126,126
$4.44
$5.00M
ORBIMED ADVISORS LLC
21 Apr 2026
Director
Buy indirect
1,689,189
$4.44
$7.50M
Bonita David P
21 Apr 2026
Director
Buy indirect
1,126,126
$4.44
$5.00M
Bonita David P
21 Apr 2026
Director
Buy indirect
1,689,189
$4.44
$7.50M

What was left out

Form 4 filings counted 18
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 4
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 1,419,730
History held since 28 Sep 2020